Listing Performance
▲ 31.78%
Issue Price
₹343
Listing Price
₹452
Listed On
29 May 2026
- Price Band
- ₹326 – ₹343
- Lot Size
- 400
- Lot Value
- ₹1,37,200
- Open Date
- 21 May 2026
- Close Date
- 25 May 2026
- Min Investment
- ₹1,37,200
Q-Line Biotech — Live Stock Performance
IPO Timeline
Issue Opens
21 May 2026 · Thu
Issue Closes
25 May 2026 · Mon
Bidding Cut-off (UPI Mandate)
25 May 2026 · 5:00 PM IST
Allotment
26 May 2026 · Tue
Listing
29 May 2026 · Fri
About Q-Line Biotech
Manufactures and sells diagnostic reagents, analytical machines (Selectra), and consumer healthcare products through a network of distributors, including group entity POCT Services.
Investment Analysis
Quick Analysis: 6 strengths · 6 risk factors· Exchange: NSE SME
Strengths (6)
- •Established manufacturing with focus on R&D, reverse engineering, quality control
- •Diversified product portfolio emphasizing in vitro diagnostic industry
- •Widespread distribution network across all four regions
- •Long-standing relationships with customers
- •Track record of healthy financial performance
- •Experienced promoter and management team
Risk Factors (6)
- •Manufacturing facility disruptions across 4 plants could adversely affect business, cash flows, and operations
- •Regulatory changes in IVD industry and product approvals could impact market access and competitiveness
- •Competition from established players with greater resources may erode market share and profitability
- •Dependence on key personnel and promoters poses succession and operational continuity risks
- •Product quality or safety issues could trigger recalls, liability, and reputational damage
- •Supply chain disruptions or raw material price volatility could increase costs and reduce margins
📊 Algorithmic Score
Computed from issue structure — GMP, fresh issue %, OFS %, issue size
Why do these differ? The Algorithmic Score measures issue quality (structure, size, promoter commitment). The Demand Analysis measures investor interest signals (subscription, GMP, risks). A high-quality issue can still have unconfirmed demand — especially before subscription opens.
✍️ Demand & Risk Analysis
Based on market demand signals — subscription, GMP trend, risk factors
IPO Market Analysis
▲ Listed +31.8%Strong investor demand with 102x subscription suggests positive listing momentum. GMP indicates market expects a listing premium.
Pre-listing prediction: SUBSCRIBE
IPO Details
| Registrar | Purva Sharegistry (India) Pvt.Ltd. |
| Exchange | NSE SME |
| ISIN | — |
| Face Value | ₹10 |
| Issue Size | ₹251.00 Cr |
| Fresh Issue | — |
| OFS Size | — |
| Lead Managers | HEM SECURITIES LIMITED, SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED |
Company Fundamentals
11 sections extracted from this filingCapital Structure
| Authorised Capital | ₹25.00 Cr |
| Issued Capital | ₹17.07 Cr |
| Paid-up Capital | ₹17.07 Cr |
| Equity Shares (Pre-Issue) | 1,70,74,999 |
| Equity Shares (Post-Issue) | — |
| Preference Shares | 0 |
| ESOP Outstanding | 0 |
Source: Q-Line Biotech offer document (DRHP/RHP).
Shareholding Pattern
Pre-Issue
Pre-Issue not disclosed in this filing.Not separately disclosed in Q-Line Biotech's filing.
Post-Issue
Post-Issue not disclosed in this filing.Not separately disclosed in Q-Line Biotech's filing.
Source: Q-Line Biotech offer document (DRHP/RHP).
Reservations & OFS
Investor Reservation
- QIB+50.00%
- NII / HNI+15.00%
- Retail+35.00%
OFS Selling Shareholders
No offer-for-sale component (or sellers not disclosed).
Source: Q-Line Biotech offer document (DRHP/RHP).
Board & Management
Board of Directors (9)
- Saurabh Garg₹0.00 Cr p.a.
Chairman & Managing Director
Promoter and founder with extensive business experience
- Kuldeep Chowdhry₹0.63 Cr p.a.
Whole Time Director
- Ajay Kumar Mahanty₹0.98 Cr p.a.
Whole Time Director
Master of Business Administration & Bachelor of Science
- Yethadka Subraya Prabhakara
Whole Time Director
Bachelor of Science (Agricultural Marketing and Co-operation), Master of Science (Agricultural Economics) and Post Graduate Diploma in Management (Agriculture)
- Pravir Kumar
Independent Director
- Abhishek Mishra
Independent Director
- Amita Garg
Non-Executive Director
- Ayush Garg
Non-Executive Director
- Abhay Agrawal
Non-Executive Director
Key Managerial Personnel (6)
- Saurabh Garg₹0.00 Cr p.a.
Chairman & Managing Director
Promoter with extensive business experience
- Kuldeep Chowdhry₹0.63 Cr p.a.
Whole Time Director
- Ajay Kumar Mahanty₹0.98 Cr p.a.
Whole Time Director
Master of Business Administration & Bachelor of Science
- Yethadka Subraya Prabhakara
Whole Time Director
Bachelor of Science (Agricultural Marketing and Co-operation), Master of Science (Agricultural Economics) and Post Graduate Diploma in Management (Agriculture)
- Meenal Gupta₹0.03 Cr p.a.
Chief Financial Officer
Chartered Accountant and Bachelor of Commerce (Honours)
Over 15 years in financial operations including strategic planning, financial evaluation, risk management
- Akhand Pratap Singh₹0.01 Cr p.a.
Company Secretary & Compliance Officer
Company Secretary and Bachelor of Commerce
Over 7 years in corporate governance, secretarial functions, legal compliance and regulatory affairs
Source: Q-Line Biotech offer document (DRHP/RHP).
Industry & Market
Industry & market data not disclosed in this filing.Market-size/industry detail was not extracted from Q-Line Biotech's filing.
Use of IPO Proceeds
Total allocation: ₹183.50 Cr (excludes issue expenses)
Promoters
Saurabh Garg
Chairman & Managing Director · age 55
Around 31 years of experience in healthcare and diagnostic industry.
Pre-issue: 59.68% · Post-issue: 43.69%
Amita Garg
Non-Executive Director · age 51
Around 15 years of experience in healthcare and diagnostic industry.
Pre-issue: 23.06% · Post-issue: 16.88%
Ayush Garg
Non-Executive Director · age 24
Around 5 years of experience in healthcare and diagnostic industry.
Pre-issue: 0.18% · Post-issue: 0.14%
Ajay Kumar Mahanty
Whole Time Director · age 48
Around 20 years of experience in healthcare and diagnostic industry.
Pre-issue: 4.39% · Post-issue: 3.21%
Abhay Agrawal
Non-Executive Director · age 47
Around 17 years of experience in healthcare and diagnostic industry.
Pre-issue: 4.43% · Post-issue: 3.24%
Investor Quota
Approx. shares reserved per category
Estimated from total issue size; actual reserved lots are set in the RHP.
Application Lot Sizes
Retail caps at ₹2,00,000 (13 lots here). S-HNI is ₹2L–₹10L, B-HNI is above ₹10L.
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 400 | ₹1,37,200 |
| Retail (max) | 13 | 5,200 | ₹17,83,600 |
| S-HNI (min) | 14 | 5,600 | ₹19,20,800 |
| S-HNI (max) | 66 | 26,400 | ₹90,55,200 |
| B-HNI (min) | 67 | 26,800 | ₹91,92,400 |
Peer Comparison
| Company | P/E | EPS | RoNW % | NAV |
|---|---|---|---|---|
| Q-line Biotech Limited | — | 28.63 | 23.74 | 120.6 |
Material Litigation
| Type | Against | Matters | Amount (₹Cr) |
|---|---|---|---|
| Criminal | Promoters | 1 | — |
| Civil | Promoters | 1 | 2.76 |
| Tax | Promoters | 11 | — |
| Tax | Company | 3 | 0.035 |
| Civil | Directors | 1 | — |
Promoters Saurabh Garg and Amita Garg were subject to Income Tax Department search and seizure operations (September 2-5, 2025) with documents seized; a summon was issued to Saurabh Garg on December 9, 2025 under section 131(1A) of the Income Tax Act 1961, pending adjudication. POCT Services (partnership firm with promoter partners) faces multiple income tax demands totaling approximately ₹15.57 lakhs across assessment years 2011 and 2013, with notices issued and matters pending.
Registrar (RTA)
SEBI-registered Registrar & Transfer Agent — handles allotment and refunds.
Registrar:Purva Sharegistry (India) Pvt.Ltd.→Lead Managers (BRLMs)
Click any merchant banker for their full IPO track record (positive listing rate, average gain, IPOs managed).
3-Year Financial Summary
Revenue trend
↑ FY23→FY25
| Fiscal Year | Revenue (₹Cr) | PAT (₹Cr) | EPS | P/E | ROE |
|---|---|---|---|---|---|
| FY25 | 313.78 | 28.13 | 28.63 | — | 23.74% |
| FY24 | 203.65 | 34.45 | — | — | — |
| FY23 | 182.74 | 32.1 | — | — | — |
Detailed Line Items (₹ Cr)
| Line Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| EBITDA | 32.98 | 37.63 | 71.32 |
| Net Worth | 125.79 | 160.24 | 188.37 |
From the company's offer document (DRHP/RHP); restated figures where available.
Valuation at Issue Price
Issue P/E
12.0x
Price ÷ EPS
EPS (FY25)
₹29
Earnings per share
RoNW
23.74%
Return on net worth
ROCE
17.66%
as reported in filing
EBITDA margin
22.7%
EBITDA ÷ revenue
Price/NAV
2.84x
Price ÷ NAV (as reported)
Subscription Status
| Category | Day 1 | Day 5 |
|---|---|---|
| QIB | — | 123.94x |
| sNII (S-HNI) | — | — |
| bNII (B-HNI) | — | — |
| Retail | — | 71.39x |
| Total | — | 102.47x |
Colour: red <1x · green 1–5x · blue 5–10x · orange >10x.
Allotment Statistics
Retail Individual Investors (RII)
Subscription
71.39x
Allotment Ratio
1 lot per 72 applicants
Allotment Probability
~1.4%
Non-Institutional Investors (NII / HNI)
Subscription
146.33x
Allotment Type
Proportionate allotment
Qualified Institutional Buyers (QIB)
Subscription
123.94x
Allotment Type
Discretionary allotment
Total Subscription
102.47x
Allotment probability is estimated based on subscription data and is not guaranteed. Actual allotment depends on the registrar's process.
Basis of Allotment
Category-wise subscription & allotment ratio
Recently Listed IPOs
| Company | Listed | Listing Gain |
|---|---|---|
| Crazy Snacks | 03 Jul 2026 | — |
| Dhanwel Hybrid Seeds | 02 Jul 2026 | — |
| Sri Priyanka Geo Commex | 02 Jul 2026 | — |
Related IPOs
Documents
Frequently Asked Questions
When is the Q-Line Biotech IPO opening?
The Q-Line Biotech IPO opens on 21 May 2026 and closes on 25 May 2026. Check this page for the latest updates as we refresh every 30 minutes.
What is the price band of the Q-Line Biotech IPO?
The price band for the Q-Line Biotech IPO is ₹326 to ₹343. The final price is announced after the book-building process and is confirmed before listing.
What is the lot size and minimum investment for the Q-Line Biotech IPO?
The minimum lot size is 400 shares with a minimum investment of ₹1,37,200. Retail investors can apply for up to the retail limit defined by SEBI.
What is the GMP of Q-Line Biotech IPO today?
The latest Grey Market Premium for Q-Line Biotech is ₹126 (+37.00%). GMP is unofficial data and is not a guarantee of listing price.
When will the Q-Line Biotech IPO list on NSE and BSE?
The Q-Line Biotech IPO is expected to list on 29 May 2026 on NSE SME. Actual listing day trading begins at the start of the normal market session.
How can I check the Q-Line Biotech IPO allotment status?
The registrar for this IPO is Purva Sharegistry (India) Pvt.Ltd.. You can check your allotment status on the registrar's portal using your PAN, application number, or DP ID. We link to the registrar directly on our allotment page after the allotment date.
Is the Q-Line Biotech IPO a mainboard or SME issue?
Q-Line Biotech is a SME IPO that will list on the NSE Emerge or BSE SME platform. SME IPOs require a minimum application value of one lakh rupees.
How do I apply for the Q-Line Biotech IPO?
You can apply for the Q-Line Biotech IPO through any SEBI-registered broker such as Zerodha, Upstox, or Angel One using UPI or ASBA. Use the Apply Now buttons on this page to go directly to the broker.
What is the expected listing price of Q-Line Biotech IPO?
Based on the current GMP of ₹126, the expected listing price of Q-Line Biotech is ₹469 (issue price ₹343 + GMP ₹126). Note that GMP is unofficial grey market data and actual listing price may differ.
What is the allotment ratio for Q-Line Biotech IPO?
Based on the retail subscription of 71.39x, the estimated allotment ratio is 1 lot per 72 applicants (approximately 1.4% chance of allotment). This is an estimate and actual allotment may vary.
Should I subscribe to Q-Line Biotech IPO?
Based on our algorithmic analysis, Q-Line Biotech IPO is rated SUBSCRIBE with high confidence. Strong investor demand with 102x subscription suggests positive listing momentum. GMP indicates market expects a listing premium. This is not investment advice — please read the DRHP and consult a financial advisor before investing.
Related Articles
How to Apply for IPO Online Through UPI in 2026 — Zerodha, Groww, Upstox Guide
Complete guide to applying for an IPO online in India 2026. Step-by-step instructions for Zerodha, Upstox, Angel One, and ASBA net banking.
Read more →
How-ToHow to Check IPO Allotment Status — All Registrar Portals Guide 2026
Step-by-step guide to check IPO allotment status on KFintech, MUFG Intime, Bigshare, BSE and NSE portals using PAN, application number or DP ID.
Read more →
How-ToIPO Allotment Process Explained — How Shares Are Distributed to Investors
Understand how IPO allotment works in India — the lottery system for retail, proportionate allotment for HNIs, QIB allocation, and what happens after allotment.
Read more →